---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-034120"
form_type: "8-K/A"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:29:41.632880+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OSR Holdings files audited FY2024 financials for Legacy OSR; net loss widens to ₩14.1B

## Summary
- Net loss of ₩14.09B (₩7,466 per share) for 2024 vs ₩13.61B loss in 2023 on revenue of ₩4.82B (+8% YoY).
- Operating loss increased to ₩15.95B from ₩14.78B; SG&A expenses grew to ₩17.05B.
- Total assets ₩257.6B, equity ₩210.5B; cash and equivalents dropped to ₩502M from ₩697M.
- Key subsidiaries: VAXIMM (Switzerland, biotech), RMC (medical devices, Korea), Darnatein (biotech, Korea).

## SEC filing metadata
- accession: 0001213900-25-034120
- form_type: 8-K/A
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000121390025034120/0001213900-25-034120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000121390025034120/ea0238120-8ka1_osr.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-034120
- JSON: https://secwatch.observer/filing/0001213900-25-034120.json
- Plain text: https://secwatch.observer/filing/0001213900-25-034120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.